Graf Acquisition Corp. IV
GFOR-UN
New York Stock Exchange8.35
USD
+2.30
- -
CIK
0001845459
Return %
Stock
S&P500
1Y
-14.97
26.84
3Y
-15.91
77.03
5Y
-15.91
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- James A. Graf
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1790 Hughes Landing Boulevard The Woodlands TX United States of America 77380
- IPO Date
- May 21, 2021
- CIK
- 0001845459
- Website
- grafacq.com
- Similar Companies
- Business
- Graf Acquisition Corp. IV is a special purpose acquisition company (SPAC) primarily focused on effecting mergers, acquisitions, and business combinations across various industries. Founded in 2021 and headquartered in The Woodlands, Texas, the company targets opportunities in diverse sectors including mobility, technology, transportation, new energy, software, infrastructure, consumer, defense and cybersecurity, business and real estate services, financial and data services, healthcare, diversified industrial manufacturing, and distribution services. Its business model involves seeking and acquiring a target company to become a publicly listed entity through a reverse merger or other business combination transactions. A recent major development for Graf Acquisition Corp. IV is its definitive business combination agreement with NKGen Biotech, Inc., a clinical-stage biotechnology company specializing in the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapies. NKGen Biotech is based in Santa Ana, California, and focuses on advanced cell therapies for oncology and immune-related conditions. Upon completion of the business combination, Graf Acquisition Corp. IV will be renamed NKGen Biotech, Inc. and is expected to be listed on a major U.S. exchange, including the New York Stock Exchange or Nasdaq under the ticker symbol "NKGN." The transaction represents a strategic pivot from a blank-check SPAC to a biotechnology operating company with an advanced therapeutic pipeline. Graf Acquisition Corp. IV’s core current activities include capital raising through public offerings and pursuing the consummation of the approved business combination. The company recently completed an initial public offering raising $150 million to fund these efforts. It has engaged in ongoing financing activities and received certain amendments such as NKGen waiving a minimum cash condition to facilitate the merger. The company has also adjourned shareholder meetings as part of the process to secure necessary approvals and financing to complete the business combination. In summary, Graf Acquisition Corp. IV operates as a SPAC focused on acquiring businesses in technology and healthcare, with its latest strategic development being the announced business combination with NKGen Biotech, a clinical-stage natural killer cell therapy developer, representing a transition to a biotechnology operating company. This description incorporates the latest company activities, business model, product focus of the acquired target, and recent structural changes including the planned renaming and exchange listing after the combination. The company's headquarters remain in Texas, while its operations will extend into advanced biotechnology markets through NKGen Biotech. The new entity will continue research, development, and commercialization of CAR-NK and related immunotherapies.